EIF4B is a Convergent Target and Critical Effector of Oncogenic Pim and PI3K/Akt/mTOR Signaling Pathways in Abl Transformants

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Feb 6

PMID 26848623

Citations 16

Authors

Ke Chen

Jianling Yang

Jianning Li

Xuefei Wang

Yuhai Chen

Shile Huang

Ji-Long Chen

Affiliations

Soon will be listed here.

Abstract

Activation of eIF4B correlates with Abl-mediated cellular transformation, but the precise mechanisms are largely unknown. Here we show that eIF4B is a convergent substrate of JAK/STAT/Pim and PI3K/Akt/mTOR pathways in Abl transformants. Both pathways phosphorylated eIF4B in Abl-transformed cells, and such redundant regulation was responsible for the limited effect of single inhibitor on Abl oncogenicity. Persistent inhibition of one signaling pathway induced the activation of the other pathway and thereby restored the phosphorylation levels of eIF4B. Simultaneous inhibition of the two pathways impaired eIF4B phosphorylation more effectively, and synergistically induced apoptosis in Abl transformed cells and inhibited the growth of engrafted tumors in nude mice. Similarly, the survival of Abl transformants exhibited a higher sensitivity to the pharmacological inhibition, when combined with the shRNA-based silence of the other pathway. Interestingly, such synergy was dependent on the phosphorylation status of eIF4B on Ser422, as overexpression of eIF4B phosphomimetic mutant S422E in the transformants greatly attenuated the synergistic effects of these inhibitors on Abl oncogenicity. In contrast, eIF4B knockdown sensitized Abl transformants to undergo apoptosis induced by the combined blockage. Collectively, the results indicate that eIF4B integrates the signals from Pim and PI3K/Akt/mTOR pathways in Abl-expressing leukemic cells, and is a promising therapeutic target for such cancers.

Citing Articles

Complex CDKL5 translational regulation and its potential role in CDKL5 deficiency disorder.

Ruggiero V, Fagioli C, de Pretis S, Di Carlo V, Landsberger N, Zacchetti D Front Cell Neurosci. 2023; 17:1231493.

PMID: 37964795 PMC: 10642286. DOI: 10.3389/fncel.2023.1231493.

Curcumin analog GO-Y030 inhibits tumor metastasis and glycolysis.

Maruyama T, Miyazaki H, Komori T, Osana S, Shibata H, Owada Y J Biochem. 2023; 174(6):511-518.

PMID: 37656908 PMC: 11002536. DOI: 10.1093/jb/mvad066.

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.

Emdal K, Palacio-Escat N, Wigerup C, Eguchi A, Nilsson H, Bekker-Jensen D Cell Rep. 2022; 40(6):111177.

PMID: 35947955 PMC: 9380259. DOI: 10.1016/j.celrep.2022.111177.

A Review: PI3K/AKT/mTOR Signaling Pathway and Its Regulated Eukaryotic Translation Initiation Factors May Be a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma.

Huang R, Dai Q, Yang R, Duan Y, Zhao Q, Haybaeck J Front Oncol. 2022; 12:817916.

PMID: 35574327 PMC: 9096244. DOI: 10.3389/fonc.2022.817916.

PARK2 regulates eIF4B-driven lymphomagenesis.

Kapadia B, Roychowdhury A, Kayastha F, Nanaji N, Gartenhaus R Mol Cancer Res. 2022; .

PMID: 35191952 PMC: 9339581. DOI: 10.1158/1541-7786.MCR-21-0729.

References

Ly C, Arechiga A, Melo J, Walsh C, Ong S . Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res. 2003; 63(18):5716-22. View

Shahbazian D, Roux P, Mieulet V, Cohen M, Raught B, Taunton J . The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 2006; 25(12):2781-91. PMC: 1500846. DOI: 10.1038/sj.emboj.7601166. View

She Q, Solit D, Ye Q, OReilly K, Lobo J, Rosen N . The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 2005; 8(4):287-97. PMC: 3203692. DOI: 10.1016/j.ccr.2005.09.006. View

Horvilleur E, Sbarrato T, Hill K, Spriggs R, Screen M, Goodrem P . A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. Leukemia. 2013; 28(5):1092-102. PMC: 4017261. DOI: 10.1038/leu.2013.295. View

van Gorp A, van der Vos K, Brenkman A, Bremer A, van den Broek N, Zwartkruis F . AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene. 2008; 28(1):95-106. DOI: 10.1038/onc.2008.367. View

Chen L, Redkar S, Bearss D, Wierda W, Gandhi V . Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009; 114(19):4150-7. PMC: 2774551. DOI: 10.1182/blood-2009-03-212852. View

Zhang Y, Wang Z, Li X, Magnuson N . Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 2008; 27(35):4809-19. DOI: 10.1038/onc.2008.123. View

Fruman D, Rommel C . PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014; 13(2):140-56. PMC: 3994981. DOI: 10.1038/nrd4204. View

Holz M, Ballif B, Gygi S, Blenis J . mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005; 123(4):569-80. DOI: 10.1016/j.cell.2005.10.024. View

10.

Hsieh A, Ruggero D . Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res. 2010; 16(20):4914-20. PMC: 7539621. DOI: 10.1158/1078-0432.CCR-10-0433. View

11.

Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu V . Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci U S A. 2010; 107(6):2598-603. PMC: 2823889. DOI: 10.1073/pnas.0914018107. View

12.

Guo G, Qiu X, Wang S, Rothman P, Wang Z, Chen Y . Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene. 2010; 29(26):3845-53. DOI: 10.1038/onc.2010.149. View

13.

Marega M, Piazza R, Pirola A, Redaelli S, Mogavero A, Iacobucci I . BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Leukemia. 2010; 24(8):1445-9. DOI: 10.1038/leu.2010.101. View

14.

Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U . JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 2012; 22(6):796-811. DOI: 10.1016/j.ccr.2012.10.023. View

15.

Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K . The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia. 2011; 25(7):1182-8. DOI: 10.1038/leu.2011.60. View

16.

Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N . eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle. 2010; 9(20):4106-9. PMC: 3055195. DOI: 10.4161/cc.9.20.13630. View

17.

Hernandez G, Vazquez-Pianzola P, Zurbriggen A, Altmann M, Sierra J, Rivera-Pomar R . Two functionally redundant isoforms of Drosophila melanogaster eukaryotic initiation factor 4B are involved in cap-dependent translation, cell survival, and proliferation. Eur J Biochem. 2004; 271(14):2923-36. DOI: 10.1111/j.1432-1033.2004.04217.x. View

18.

Low W, Dang Y, Schneider-Poetsch T, Shi Z, Choi N, Merrick W . Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell. 2005; 20(5):709-22. DOI: 10.1016/j.molcel.2005.10.008. View

19.

Chou T . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-81. DOI: 10.1124/pr.58.3.10. View

20.

Chen J, Limnander A, Rothman P . Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood. 2007; 111(3):1677-85. DOI: 10.1182/blood-2007-04-083808. View